March 29, 2021

Bio Products Laboratory (BPL), a specialist manufacturer of plasma-derived medicinal products, announces that it will be investing £23m to build a new Sterile Filling Suite at its Elstree site in the UK. From its base in Hertfordshire, BPL fractionates plasma to manufacture therapeutic products which are then supplied to patients in more than 45 countries around the world.

This expansion of BPL’s filling capacity supports the increasing global needs for plasma-derived medicinal products. It will also provide capacity to manufacture upcoming new products which are currently in development at BPL. The 1,000m2 state-of-the-art suite will be built within an extended and re-purposed area.

The construction is planned to commence in 2021, with the new facility becoming operational by the end of 2023.

Richard Gray, Chief Operations Officer, BPL Therapeutics, commented:

“We are delighted to announce this investment, which further contributes to our long-term growth strategy and adds to our capabilities as a global supplier from our base here in the UK. We look forward to the benefits that this investment will bring to our patients and to the wider benefits that this investment brings to our employees, our community and our business.”

About Bio Products Laboratory (BPL)

BPL is a specialist manufacturer of plasma-derived medicinal products for application in immunology, treatment of coagulation disorders and critical care. Headquartered in UK, BPL Group comprises BPL Therapeutics, employing 1,000 staff in its manufacturing, quality, R&D and commercial operations at Elstree, UK; and BPL Plasma, which provides a secure supply of plasma for fractionation in UK from its 26 US-based plasma collection centres employing 900 staff. BPL’s precision products are then commercially available in more than 45 countries worldwide.

In its current form, BPL was created in 2010, but its roots stretch back several decades to the early pioneers of blood and plasma-derived medicines in UK. The business has its foundation on its core immunoglobulin and albumin-based therapies, with a growing emphasis on the development of specialty products for rare and orphan diseases.

BPL invests in the latest R&D, technology and manufacturing methods. BPL’s purpose is to fulfill the needs of patients by providing a continuous supply of reliable, high-quality plasma-derived therapies worldwide, enhancing lives and supporting both healthcare professionals and patients every day.

Media Enquiries:

Sofia Newitt, Vico Partners
+44-(0)20 3957 5045